Research
Energy balance
There is limited clinical trial data on the safety and efficacy of anti-obesity medications for patients with heart failure.
Practitioners should be aware of the limited evidence when considering anti-obesity medications for heart failure patients.
StrongQualifiesmedium confidence
clinical trials data supporting the safety and efficacy of treating obesity in patients with HF is currently limited.
Why this rating
The claim is based on the current state of clinical trial data.
Source
Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Josephine Harrington et al. · Circulation Heart Failure · 2024
DOI 10.1161/circheartfailure.124.011518
reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Anti-obesity medications, particularly glucagon-like peptide-1 receptor agonists, have shown safety and weight loss efficacy in patients with heart failure with preserved ejection fraction.Strong
- The use of anti-obesity medications in patients with heart failure may improve functional status, biomarkers of inflammation, and heart failure stability.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →